INS and breast cancer: The higher risk of breast cancer mortality seen in the patients with exposure to exogenous insulin for ≥3 or ≥5 years (Table 3) indicates an appropriate period for incubation, which should eliminate the concern of biological plausibility associated with a short duration of exposure.